Trade name approval for a new topical foam to treat psoriasis

As of February 2019, adults with plaque psoriasis have a new topical option for their treatment with the introduction of Lexette (halobetasol propionate, 0.05%) . On April 30, 2019, the U.S. Food and Drug Administration (FDA) approved the trade name Lexette (halobetasol propionate, 0.05%), for the foam-based corticosteroid. 

Manufactured by Australia-based Mayne Pharma, Lexette is a new formulation of halobetasol, which can reduce itching, scaling, redness and swelling associated with psoriasis. The topical is designed to be used by applying a thin layer on affected areas of the skin and rubbed into the skin twice a day for as long as prescribed by your health care provider. 

Jeffrey M. Weinberg, M.D., dermatologist at Mount Sinai in New York and NPF medical board member, says that now halobetasol can be delivered via a foam, the effective corticosteroid can expand to more use cases and patients. 

“This is a useful addition to our treatment armamentarium,” says Weinberg. “Halobetasol has been a go-to product for the treatment of psoriasis for over 20 years. A foam version of this compound gives clinicians the versatility to use it in additional areas of the body, including the scalp and hair-bearing areas.”

More than $19 million has been invested in psoriatic disease research since 1987 thanks to NPF grants and fellowships. This funding has had a direct impact on the research and development of new treatment options. NPF also helps connect patients with clinical trials so that more therapies can be tested and approved.

Once a drug receives FDA approval, NPF provides the latest information on treatment options to health care providers and ensures you have access to the best health care possible

Learn more about your treatment options
The NPF Patient Navigation Center can assist you in information on the latest treatments, including Lexette foam, and can help you find the right health care provider in your area. 


Driving discovery, creating community

For more than 50 years, we’ve been driving efforts to cure psoriatic disease and improve the lives of those affected. But there’s still plenty to do! Learn how you can help our advocacy team shape the laws and policies that affect people with psoriasis and psoriatic arthritis – in your state and across the country. Help us raise funds to support research by joining Team NPF, where you can walk, run, cycle, play bingo or create your own fundraising event. If you or someone you love needs free, personalized support for living a healthier life with psoriatic disease, contact our Patient Navigation Center. And keep the National Psoriasis Foundation going strong by making a donation today. Together, we will find a cure.

Recent Advance Posts

Dr. Ronald Prussick
A chance meeting with an inspiring mentor channels a promising physician into a...
hand with arthritis on mouse beside keyboard
We take many common movements and activities for granted – until they become...
genital psoriasis
One in four of you will experience genital psoriasis. Relief starts with having...
image of foam with the words "FDA approved"
Lexette, a topical corticosteroid foam, aims to reduce plaques.
FDA Approved Topical
The latest topical lotion aims to reduce plaque and clear your skin.
FDA Approval Skyrizi
The latest interleukin-23 inhibitor is aimed at adults with moderate-to-severe...
Jawbone, chatter teeth
Candace Primack experienced mysterious jaw pain during graduate school. Fifteen...
Don’t turn taking your meds into an uphill battle. Get the facts and stay the...
The first two AAD-NPF guidelines in a series of six tackle biologics and...